miR-202 suppresses proliferation and induces apoptosis of osteosarcoma cells by downregulating Gli2

Molecular and Cellular Biochemistry

Volumn 397, Issue 1-2, 2014, Pages 277-283

  Sun, Zhengwen ^a   Zhang, Tongqing ^a   Hong, Huanyu ^a   Liu, Qingxia ^a   Zhang, Haiguang ^a  

^a YANTAISHAN HOSPITAL   (China)

Author keywords

Apoptosis; Gli2; miR 202; Osteosarcoma; Proliferation

Indexed keywords

MICRORNA; MICRORNA 202; TRANSCRIPTION FACTOR GLI2; UNCLASSIFIED DRUG; GLI2 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR; MIRN202 MICRORNA, HUMAN; NUCLEAR PROTEIN; RNA; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PROTEIN RNA BINDING; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BONE TUMOR; CANCER TRANSPLANTATION; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NUCLEAR PROTEINS; OSTEOSARCOMA; RNA, NEOPLASM;

EID: 84911910037     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-014-2195-z     Document Type: Article

References (29)

1. Ando K, Heymann MF, Stresing V, Mori K, Redini F, Heymann D (2013) Current therapeutic strategies and novel approaches in osteosarcoma. Cancers (Basel) 5:591–616. doi:10.3390/cancers5020591
2. Broadhead ML, Clark JC, Myers DE, Dass CR, Choong PF (2011) The molecular pathogenesis of osteosarcoma: a review. Sarcoma 2011:959248. doi:10.1155/2011/959248
3. Gorlick R (2009) Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res 152:467–478. doi:10.1007/978-1-4419-0284-9_27
4. Marina N, Gebhardt M, Teot L, Gorlick R (2004) Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9:422–441
5. Lulla RR, Costa FF, Bischof JM, Chou PM, de F BM, Vanin EF, Soares MB (2011) Identification of differentially expressed microRNAs in osteosarcoma. Sarcoma 2011:732690. doi: 10.1155/2011/732690
6. Osaki M, Takeshita F, Sugimoto Y, Kosaka N, Yamamoto Y, Yoshioka Y, Kobayashi E, Yamada T, Kawai A, Inoue T, Ito H, Oshimura M, Ochiya T (2011) MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther 19:1123–1130. doi:10.1038/mt.2011.53
7. Jones KB, Salah Z, Del MS, Galasso M, Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, Volinia S, Stein GS, Croce CM, Lian JB, Aqeilan RI (2012) miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res 72:1865–1877. doi:10.1158/0008-5472.CAN-11-2663
8. Garzon R, Calin GA, Croce CM (2009) MicroRNAs in Cancer. Annu Rev Med 60:167–179. doi:10.1146/annurev.med.59.053006.104707
9. Liu J (2008) Control of protein synthesis and mRNA degradation by microRNAs. Curr Opin Cell Biol 20:214–221. doi:10.1016/j.ceb.2008.01.006
10. Ambros V (2004) The functions of animal microRNAs. Nature 431:350–355
11. Zhao Y, Srivastava D (2007) A developmental view of microRNA function. Trends Biochem Sci 32:189–197
12. Croce CM (2009) Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10:704–714. doi:10.1038/nrg2634
13. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, Benjamin H, Shabes N, Tabak S, Levy A, Lebanony D, Goren Y, Silberschein E, Targan N, Ben-Ari A, Gilad S, Sion-Vardy N, Tobar A, Feinmesser M, Kharenko O, Nativ O, Nass D, Perelman M, Yosepovich A, Shalmon B, Polak-Charcon S, Fridman E, Avniel A, Bentwich I, Bentwich Z, Cohen D, Chajut A, Barshack I (2008) MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 26:462–469. doi:10.1038/nbt1392
14. Shenouda SK, Alahari SK (2009) MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev 28:369–378. doi:10.1007/s10555-009-9188-5
15. Peiffer SL, Herzog TJ, Tribune DJ, Mutch DG, Gersell DJ, Goodfellow PJ (1995) Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers. Cancer Res 55:1922–1926
16. Wang Q, Huang Z, Guo W, Ni S, Xiao X, Wang L, Huang D, Tan C, Xu Q, Zha R, Zhang J, Sheng W, He X, Du X (2014) microRNA-202-3p inhibits cell proliferation by targeting ADP-ribosylation factor-like 5A in human colorectal carcinoma. Clin Cancer Res 20:1146–1157. doi:10.1158/1078-0432.CCR-13-1023
17. Zhang Y, Zheng D, Xiong Y, Xue C, Chen G, Yan B, Ye Q (2014) miR-202 suppresses cell proliferation in human hepatocellular carcinoma by downregulating LRP6 post-transcriptionally. FEBS Lett 588:1913–1920. doi:10.1016/j.febslet.2014.03.030
18. Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahmann L, Loehberg CR, Lux MP, Jud SM, Hartmann A, Hein A, Bayer CM, Bani MR, Richter S, Adamietz BR, Wenkel E, Rauh C, Beckmann MW, Fasching PA (2012) Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One 7:e29770. doi:10.1371/journal.pone.0029770
19. Yu J, Qiu X, Shen X, Shi W, Wu X, Gu G, Zhu B, Ju S (2014) miR-202 expression concentration and its clinical significance in the serum of multiple myeloma patients. Ann Clin Biochem 51:543–549
20. Zhao Y, Li C, Wang M, Su L, Qu Y, Li J, Yu B, Yan M, Yu Y, Liu B, Zhu Z (2013) Decrease of miR-202-3p expression, a novel tumor suppressor, in gastric cancer. PLoS One 8:e69756. doi:10.1371/journal.pone.0069756
21. Hoffman AE, Liu R, Fu A, Zheng T, Slack F, Zhu Y (2013) Targetome profiling, pathway analysis and genetic association study implicate miR-202 in lymphomagenesis. Cancer Epidemiol Biomarkers Prev 22:327–336. doi:10.1158/1055-9965
22. Buechner J, Tomte E, Haug BH, Henriksen JR, Lokke C, Flaegstad T, Einvik C (2011) Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br J Cancer 105:296–303. doi:10.1038/bjc.2011.220
23. Yang W, Liu X, Choy E, Mankin H, Hornicek FJ, Duan Z (2013) Targeting hedgehog-GLI-2 pathway in osteosarcoma. J Orthop Res 31:502–509. doi:10.1002/jor.22230
24. Scales SJ, de Sauvage FJ (2009) Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 30:303–312. doi:10.1016/j.tips.2009.03.007
25. Ji F, Zhang H, Wang Y, Li M, Xu W, Kang Y, Wang Z, Wang Z, Cheng P, Tong D, Li C, Tang H (2013) MicroRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1. Bone 56:220–226. doi:10.1016/j.bone.2013.05.020
26. Kobayashi E, Hornicek FJ, Duan Z (2012) MicroRNA involvement in osteosarcoma. Sarcoma 2012:359739. doi:10.1155/2012/359739
27. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR (2005) MicroRNA expression profiles classify human cancers. Nature 435:834–838
28. Regl G, Neill GW, Eichberger T, Kasper M, Ikram MS, Koller J, Hintner H, Quinn AG, Frischauf AM, Aberger F (2002) Human GLI2 and GLI1 are part of a positive feedback mechanism in Basal Cell Carcinoma. Oncogene 21:5529–5539
29. Nagao H, Ijiri K, Hirotsu M, Ishidou Y, Yamamoto T, Nagano S, Takizawa T, Nakashima K, Komiya S, Setoguchi T (2011) Role of GLI2 in the growth of human osteosarcoma. J Pathol 224:169–179. doi:10.1002/path.2880